Ivosidenib + MFOLFIRINOX In Patients With Resectable Pancreatic Adenocarcinoma

Study Overview

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.

Currently, the standard of care treatment for resectable PDA is surgical resection followed by adjuvant chemotherapy. The use of mFOLFIRINOX in this setting has extended survival significantly. Giving ivosidenibwith mFOLFIRINOXmay work better than treating participants with mFOLFIRINOX alone.

Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Cancer

DRUG: Ivosidenib
DRUG: mFOLFIRINOX

CASE7221

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2022-01-12	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-09-03
First Submitted that Met QC Criteria 2022-01-12	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2025-09-05
First Posted (ESTIMATED) 2022-01-26	Results First Posted N/A	Last Verified 2025-09

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Ivosidenib+mFOLFIRINOX	DRUG: Ivosidenib Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle. DRUG: mFOLFIRINOX mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Ivosidenib+mFOLFIRINOX

DRUG: Ivosidenib

Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.

DRUG: mFOLFIRINOX

mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.

Primary Outcome Measures	Measure Description	Time Frame
Maximum-tolerated dose (MTD) or Recommended Phase 2 dose (RP2D)	Evaluate by the Bayesian optimal interval (BOIN) strategy to identify the MTD.	Up to 24 months from the start of treatment

Secondary Outcome Measures	Measure Description	Time Frame
RECIST version 1.1 response rates.	Number of participants with the progression-free occurrence.	Up to 24 weeks from the start of treatment
Major pathologic response rates	Number of participants in whom historical treatment's response rate of 10%	Up to 24 weeks from the start of treatment
Biochemical response rates	Number of participants with normalization of serum tumor markers during treatment and after surgery.	Up to 24 weeks from the start of treatment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Subjects must have histologicallyor cytologically confirmed diagnosis of pancreatic adenocarcinomaor adenosquamous carcinoma.
Subjects must have resectable right-sided (head/neck/uncinate) pancreatic cancer based on CT or MRI imaging (pancreas protocol CT of the abdomen and pelvis if possible, MRI with contrast or CT with IV contrast in the absence of a pancreas protocol CT scan, CT of the chest with or without contrast) as determined by the PI or Co-investigators. Participants with contrast allergies may be permitted without contrastscans if approved by the PI or Co-Investigators for safety reasons.
Male or female subjects age >18 years of age.
Eastern Cooperative Oncology Group (ECOG) Performance status being 0-1 within 2 weeks of planned start of therapy.
Subjects must have normal organ and marrow function as defined below within 2 weeks of C1D1:
Adequate hematologic (white blood cell [WBC] ≥ 3500 cells/mm3; platelet count ≥100,000 cells/mm3; absolute neutrophil count [ANC] ≥1500 cells/mm3; and hemoglobin ≥8 g/dL).
Adequate hepatic function (aspartate aminotransferase [AST/SGOT] <3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] <3x UNL, bilirubin <3x UNL).
Adequate renal function (serum creatinine <2.0 mg/dL or 177 μmol/L).
Adequate coagulation ("International Normalized Ratio" or INR must be <1.5) unless on therapeutic blood thinners.
Screening HgbA1C < 7.0%
Expected survival ≥3 months in the view of the PI or investigators.
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
Fertile men must practice effective contraceptive methods (i.e. surgical sterilization, or a condom used with a spermicide) during the study, unless documentation of infertility exists.
No evidence of clinically significant active infection and no seriousor chronicinfection requiring ongoing antibiotics during the study period.
Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Inclusion of Women and Minorities
People of all races and ethnic groups are eligible for participation in this trial.

Subjects under the age of 18yearsof age.
Subjects with unresectablepancreatic canceror resectableleft-sided (body/tail) pancreatic cancer
Subjects with endocrine or acinar pancreatic carcinoma.
Subjects with locally advanced or recurrentpancreatic cancer.
Subjects with metastatic pancreatic cancer based on imaging.
Subjects who have received prior radiation therapy, surgical or medical treatment for pancreatic cancer.
Subjects receiving any other standard or investigational treatment for their PDA.
Pregnant women or breast feeding women, or women of child-bearing potential not using reliable means of contraception are excluded from this study because the teratogenic or abortifacient effects of ivosidenibis unknown. Because there is an unknown, but potential risk for adverse events in nursinginfants secondary to treatment of the mother with ivosidenib, breastfeeding should be discontinued if the mother is treated withivosidenib. These potential risks may also apply to other agents used in this study.
Fertile men unwilling to practice contraceptive methods during the study period.
Subjects with a life expectancy less than 3 months.
Subjects with a serious medical illness that would potentially increase subjects' risk for toxicity
Subjects with any active uncontrolled bleeding, and any participants with a bleeding diathesis (e.g., active peptic ulcer disease).
Subjects with a history of myocardial infarction that is <3 months prior to registration.
Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure or coronary artery disease, unstable angina pectoris, cardiac arrhythmiarequiring medications that interact with ivosidenib, symptomatic myocardial infarction or psychiatric illness/social situations that would limit compliance with study requirements.
Subjects who are known to be HIV-positive and on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ivosidenib.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: David Bajor, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Zarei M, Hajihassani O, Hue JJ, Graor HJ, Rothermel LD, Winter JM. Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer. bioRxiv [Preprint]. 2023 Mar 29:2023.03.29.534596. doi: 10.1101/2023.03.29.534596.

Learn

Resources

PatientS

Caregivers

Clinical Trial Record